Derniers articles

Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity

Surgery of early cervical cancer has deeply evolved in the last 30 years. A de-escalation provided a similar survival...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : International Journal of Gynecological Cancer

Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO

Highlights•This study reports the largest evaluation of targeted therapies in metastatic SBA.•Antiangiogenics plus...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : European Journal of Cancer

Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer.

Abstract Cisplatin-based concurrent chemoradiation (CRT) remains the standard treatment for locally advanced head...

Posté par : Mr. Cyril BOISSON, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Oncoimmunology

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Abstract Antiphospholipid syndrome (APS) is an autoimmune condition with thrombotic and/or obstetric manifestations...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Thrombosis and Haemostasis

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process

Abstract

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Radiotherapy and Oncology

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.

Abstract Patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors or antiangiogenic...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Nature Medicine

Cancer du sein : un exemple d’évolution des pratiques intégrant les spécificités liées à l’âge. À propos de l’étude ASTER 70s

Abstract According to figures from GLOBOCAN and the European Cancer Information System, nearly 40% of breast cancers...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : La Revue du Praticien

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

AbstractContext and aimsEverolimus was approved in 2012 for the treatment of advanced hormone-receptor-positive,...

Posté par : Mr. Cyril BOISSON, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Breast Cancer Research

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)

AbstractBackgroundMicrosatellite instability (MSI) or mismatch‑repair deficiency (dMMR) defines a biologically...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Digestive and Liver Disease

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial

SummaryBackgroundThe standard of care for patients with locally advanced squamous cell anal carcinoma (SCAC) is...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Lancet Oncology

Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the A GORTEC 2014-04 “OMET” Randomized Phase 2 Trial

AbstractPurposeThe OMET GORTEC 2014-04 trial showed prolonged survival with multisite Stereotactic Ablative Body...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : International Journal of Radiation Oncology . Biology . Physics

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

AbstractPurposeImmunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Journal of Clinical Oncology

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials

AbstractPurposeThe objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Journal of Clinical Oncology

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

AbstractPurpose: Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Int J Radiat Oncol Biol Phys

SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors

AbstractBackground: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Ther Adv Med Oncol

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

AbstractBackground and objective: The CABASTY study showed that more frequent administration of a lower dose of...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : European Urology Oncology

New Biomarkers to Define A Biological Borderline Situation for Pancreatic Adenocarcinoma - Results of An Ancillary Study of the PANACHE01-PRODIGE48 Trial.

AbstractObjective: To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma (PA), the...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Annals of Surgery

A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ study

AbstractBackground: The planification of radiation therapy (RT) for pancreatic cancer (PC) requires a dosimetric...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Radiation Oncology

A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial

AbstractBackground: We assessed the added value of incorporating carcinoembryonic antigen (CEA) to circulating...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : The Oncologist

Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort

AbstractKeywords: Biliary tract cancer; CisGem; Molecular profile; Real-life data.

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Digestive and Liver Disease